Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study

Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients. To evaluate the accuracy of the available prognostic models for HCC to predict the survival of advanced HCC patients treated w...

Full description

Saved in:
Bibliographic Details
Published in:Digestive and liver disease 2021-08, Vol.53 (8), p.1011-1019
Main Authors: Marasco, Giovanni, Colecchia, Antonio, Bacchi Reggiani, Maria Letizia, Celsa, Ciro, Farinati, Fabio, Giannini, Edoardo Giovanni, Benevento, Francesca, Rapaccini, Gian Ludovico, Caturelli, Eugenio, Di Marco, Mariella, Biasini, Elisabetta, Marra, Fabio, Morisco, Filomena, Foschi, Francesco Giuseppe, Zoli, Marco, Gasbarrini, Antonio, Baroni, Gianluca Svegliati, Masotto, Alberto, Sacco, Rodolfo, Raimondo, Giovanni, Azzaroli, Francesco, Mega, Andrea, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Nardone, Gerardo, Dajti, Elton, Ravaioli, Federico, Avanzato, Francesca, Festi, Davide, Trevisani, Franco
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - mortality
Cohort study
Female
Hepatocellular carcinoma
Humans
Italy
Liver Neoplasms - drug therapy
Liver Neoplasms - mortality
Male
Middle Aged
Neoplasm Staging
Prognosis
Proportional Hazards Models
Prospective Studies
Retrospective Studies
Risk Assessment - methods
Severity of Illness Index
Sorafenib
Sorafenib - therapeutic use
Survival
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients. To evaluate the accuracy of the available prognostic models for HCC to predict the survival of advanced HCC patients treated with Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort. The performance of several prognostic scores was assessed through a Cox regression-model evaluating the C-index and the Akaike Information Criterion (AIC). Data of 1129 patients were analyzed. The mean age of patients was 61.6 years, and 80.8% were male. During a median follow-up period of 13 months, 789 patients died. The median period of Sorafenib administration was 4 months. All the prognostic scores were able to predict the overall survival (p
ISSN:1590-8658
1878-3562
DOI:10.1016/j.dld.2020.12.001